G.D. SEARLE LLC v. LUPIN PHARMACEUTICALS, INC. (Fed. Cir. 2015) (P) – Reissue cannot be used to revert an issued continuation-in-part application back to true divisional status

Reissue cannot be used to revert an issued continuation-in-part application back to true divisional status. Here, for example, a reissue application filed to revert a continuation-in-part back to a divisional application and thereby invoke safe harbor protection...

TEVA PHARMACEUTICALS USA v. SANDOZ INC. (Fed. Cir. 2015) (P) – Prosecution history estoppel applies regardless of the scientific accuracy of the statements made

A statement made during prosecution may be used to define a claim term regardless of the scientific accuracy of that statement. Here, for example, in response to identical indefiniteness rejections in separate child applications regarding the claim term “molecular...

CEPHALON, INC. v. ABRAXIS BIOSCIENCE, LLC (Fed. Cir. 2015) (NP) – A definition need only be widely rather than universally accepted to form the basis for claim construction

A definition need only be widely accepted rather than universally accepted to form a proper basis for claim construction. Here, for example, although the patentee noted that the definition of the claimed “nanoparticles” and “microparticles” as being between 1 to 1000...